The ␤-amyloid protein (␤A4), the major component of the Alzheimer-associated plaques is derived from a set of alternatively spliced ␤-amyloid precursor proteins (APP) which are encoded by a single gene located on human chromosome 21 (for a review see Selkoe, 2001) . Although the biological function of this protein remains to be fully elucidated, at physiological levels APP appears to be involved in neurotrophic events and modulates functions such as neuronal excitability, synaptic plasticity, neurite outgrowth, synaptogenesis, or cell survival (for a review see Mattson, 1997) . In contrast, its overexpression may contribute to increased production and deposit of ␤A4, and finally to activation of processes which cause cellular degeneration (Calhoun et al., 1999; Yoshikawa et al., 1992) . APP is ubiquitously expressed in mammalian tissues and its expression can be regulated by a variety of stimuli, including ligands of the nuclear superfamily of steroid/ thyroid hormone receptors (Belandia et al., 1998; Konig et al., 1990; Yoshikawa et al., 1990) , and ligands of membrane tyrosine kinase receptors (Ruiz-Leon and Pascual, 2001; Villa et al., 2001 ). The 5' promoter region of the APP gene has been cloned and characterized for both humans (Lahiri and Robakis, 1991; Salbaum et al., 1988) and rodents (Hoffman and Chernak, 1994) . The promoter lacks a TATA or CAAT boxes, but contains other consensus sequences for binding of a number of transcription factors. However, the molecular mechanisms that control its expression are not well understood.
Induction of APP expression by retinoic acid (RA) has been described in a number of cell lines of neuronal and non neuronal origin (Beckman and Iverfeldt, 1997; Hung et al., 1992; Lahiri and Nall, 1995) . The effects of RA are mediated by nuclear receptors (RARs), which normally function as ligand-inducible transcription factors by binding to response elements (RAREs) located in the regulatory region of target genes. RARs are encoded by three different genes which give rise to three different isoforms (␣, ␤ and ␥; Glass, 1994) . As has been previously described, neuroblastoma primary tumor tissue and cell lines express RAR␣, and also RAR␥ to a lesser degree. RAR␤ is expressed at very low levels, but is strongly induced by treatment with RA (Carpentier et al., 1997; Lovat et al., 1993) .
In SH-SY5Y cells, a clonal derivative of the human neuroblastoma SK-N-SH cell line which expresses high levels of RAR (Lovat et al., 1993) , RA has been shown to increase APP mRNA levels. In agreement with these results, we found that RA not only increased mRNA levels but also the levels of intracellular and secreted APP protein. However, the effects of RA on APP gene expression are delayed when compared with other effects induced by this ligand on the same cells. In addition, a 48 h treatment with RA was unable to stimulate APP promoter activity in transient transfection assays. An increased activity of the promoter was only observed following 4 -6 days of incubation in the presence of RA. These results again suggest an indirect mechanism, likely mediated by other APP promoter-interacting proteins.
Tyrosine kinase receptor B (TrkB) is the high-affinity Trk for brain-derived neurotrophic factor (BDNF), a neurotrophin that is known to promote the structure and function of the nervous system. TrkB mediates most of the BDNFinduced responses and a synergistic effect of RA and BDNF on neurite generation has been reported (Mey and Rombach, 1999) . Moreover, RA stimulates TrkB expression in neuroblastoma cells (Encinas et al., 1999; Kaplan et al., 1993; Kobayashi et al., 1994) , and as we have described, exogenous BDNF induces APP promoter activity in SH-SY5Y cells transiently transfected with an expression vector for TrkB (Ruiz-Leon and Pascual, 2001 ).
To probe a potential cross-talk between the response induced on APP by RA and BDNF in SH-SY5Y cells, we have analyzed the effects of RA on APP and TrkB expression in SH-SY5Y cells, and the effects of BDNF in SH-SY5Y cells cultured in the presence or absence of RA.
EXPERIMENTAL PROCEDURES Cell culture
SH-SY5Y cells were cultured in RPMI medium containing 10% fetal bovine serum (Gibco Life Technologies Ltd., Paislay, Scotland, UK). The same medium was used to analyze the effect induced by RA, but not the effects induced by BDNF on the APP promoter activity, which were determined in experiments carried out in RPMI medium supplemented with 0.5% serum. At the times indicated in the text, media and cells were collected and processed, or stored frozen for posterior analysis.
Chemicals
Polyclonal antibody 369A against the cytoplasmic domain of APP was a generous gift of Dr. Samuel E. Gandy and the monoclonal antibody 22C11, which recognizes the amino terminus of APP, was purchased from Boehringer Mannheim (Germany). BDNF and "all trans" RA were from PeproTech Ltd. (London, UK), and Sigma-Aldrich (St. Louis, MO, USA). The anti-TrkB monoclonal antibody was from Transduction Laboratories (Lexington, USA), and the trk inhibitor K-252a from Calbiochem (Darmstadt, Germany).
Reporter plasmids and expression vectors
The chloramphenicol acetyl transferase (CAT) reporter plasmid containing the Ϫ1099/ϩ105 fragment of the human APP gene has been previously described (Belandia et al., 1998) . The cDNA encoding the TrkB receptor was inserted into the EcoRI site of the expression vector CMV5, which contains the SV40 early promoter. The R-140-Luc construct containing the fragment Ϫ124 to ϩ14 of the human RAR␤2 promoter has been described previously by Vivanco-Ruiz et al. (1991) .
DNA transfection
SH-SY5Y cells were transfected in Dulbecco's Modified Eagle medium (DMEM) containing 10% fetal calf serum. The 10% serum-containing RPMI growing culture medium was replaced by DMEM 4 to 6 hours before transfection, and the cells were cotransfected by the calcium phosphate coprecipitation method with 5 g of the reporter plasmid (Ϫ1099CAT, or R-140-Luc) and 5 g of carrier DNA (high molecular mass calf thymus DNA). After 16 h of incubation in the presence of calcium phosphate, the medium was replaced with fresh RPMI, growing medium was added and the cells incubated in the presence or in the absence of 1 M RA for the time periods studied. In all cases, the total amount of DNA among different transfections was kept constant by addition of an empty noncoding expression vector. To analyze the effects of BDNF, RA-pretreated cells were cotransfected with the reporter plasmid Ϫ1099CAT and 2 g of a TrkB expression vector, and transfection medium replaced with 0.5% serum-containing RPMI. The cells were then cultured in the presence or in the absence of 10 g/ml BDNF. CAT activity was determined by incubation of 14 C]-chloramphenicol was quantified and the data expressed as the percentage of acetylated forms after each treatment. Each experiment was repeated at least two to three times with similar relative differences in regulated expression.
RNA extraction and hybridization
Total RNA was extracted from SH-SY5Y cells, cultured in the presence or in the absence of 1 M RA, with guanidinium thiocyanate (Chomczynski and Sacchi, 1987) . The RNA (30 g) was electrophoresed in 1% formaldehyde-agarose gels and transferred to nylon-nitrocellulose membranes for Northern blot analysis. After staining with 0.02% Methylene Blue the blots were hybridized, as described by Church and Gilbert (1984) , with a plasmid containing the human APP cDNA, or the rat TrkB cDNA, labeled by random oligonucleotide priming. Hybridization was at 65°C in PSE buffer (0.3 M sodium phosphate, pH 7.2, 7% SDS, 1 mM EDTA). The quantification of APP-mRNA levels shown in Fig. 2 was carried out by densitometric scan of the autoradiograms, and corrected by the total amount of RNA applied.
Western blot analysis
Cellular proteins were extracted by lysis with a buffer (150 mM NaCl, 50 mM Tris pH 8, 2 mM EDTA, 1% Triton X-100, 0.1% SDS) containing the protease inhibitors PMSF (1 mM) and leupeptin (10 g/ml). Equal amounts, 40 g, of cell extracts were electrophoresed in an 8% SDS-polyacrylamide gel, transferred to an immobilon polyvinylidene difluoride membrane and the cellular APP detected with the rabbit polyclonal antibody 369A. Secreted full-length APP isoforms were detected by the same method from 50 l (1:100 from total) of conditioned medium using the monoclonal antibody 22C11 at a final concentration of 10 g/ml. To determine TrkB, cellular proteins were extracted by lysis with a modified RIPA buffer (20 mM MOPS, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1% NaDOC, 0.1% SDS), in the presence of protease inhibitors, and the TrkB levels determined from 40 g aliquots with a monoclonal antibody, which recognizes both the full-length 145 kDa, and the 95 kDa forms of TrkB.
Proliferation assays: [ 3 H]thymidine incorporation
DNA synthesis rate was determined by measuring the incorporation of [ 3 H]thymidine. Cells were plated in 96-well multiwells at an initial density of 4000 cells/well. Twenty-four hours later the growing medium was replaced by RPMI (200 l) containing 10% serum and the cells were maintained at 37°C by an additional 4 day period.
[ 3 H]Thymidine (0.1 Ci) was added to the cultures during the last 6 h of incubation. The cells were then transferred to glass fiber filters and processed in a cell harvester. The radioactivity associated to filters was measured with a scintillation counter.
Statistical analysis
Results are expressed as meansϮS.D. The differences between means were evaluated by a Student's t-test and considered significant at PϽ0.05. 63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100  101  102  103  104  105  106  107  108  109  110  111  112  113  114  115  116   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54 U N C O R R E C T E D P R O O F previously described (Konig et al., 1990; Hung et al., 1992; Pan et al., 1993; Rossner et al., 1998; Yang et al., 1999) . As shown in Fig. 1 , a 4 day treatment of SH-SY5Y cells with 1 M RA, promoted morphologic differentiation (panel A) and these results were not essentially different from those reported by other authors who used 10-fold higher doses of RA (Konig et al., 1990; Beckman and Iverfeldt, 1997) . Interestingly, BDNF did not induce any morphologic change on cells when added alone, and did not further increase morphologic changes induced by RA when both agents were added together. In addition, 1 M RA also induced a strong reduction of the cellular proliferation as determined by thymidine incorporation (panel B).
RESULTS

RA induces differentiation and decreases the proliferation of SH-SY5Y cells
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Induction of APP expression by RA in SH-SY5Y cells
RA treatment of SH-SY5Y cells increases APP-mRNA levels, as well as the accumulation of intracellular and secreted isoforms of APP. The mRNA levels were determined in SH-SY5Y cells, that were incubated for 2 to 6 days in the presence or the absence of 1 M RA. As illustrated in panel A of Fig. 2 , which shows the results obtained in a representative Northern blot analysis of RNA, as well as the quantization of APP mRNA levels obtained in two independent experiments, no changes were observed after 2 days of incubation. However, a small but significant increase of APP-mRNA levels was observed after 4 -6 days of treatment with RA.
In parallel, the effects of RA on the cell-associated APP and the full-length soluble derivatives of APP released into the culture medium were analyzed by Western blot using the polyclonal antibody 369A or the monoclonal antibody 22C11, respectively. Results are depicted in panel B of Fig. 2 . As occurred with the APP-mRNA levels, the presence of 1 M RA in the culture medium for 4 days induced a significant increase of both the intracellular (left) and secreted (right) APP species.
Based on previous descriptions (Buxbaum et al., 1990; Weidemann et al., 1989) , the immunoreactive bands detected with the antibody 369A contain at least six protein species corresponding to immature and mature isoforms of APP. Incubation of SH-SY5Y cells with RA for 4 days did not affect the pattern of isoforms but led to a generalized increase of the intracellular APP content. In addition, RA induced a generalized increase of the APP-derived isoforms released to the culture medium.
Effects of RA on APP promoter activity in transiently transfected SH-SY5Y cells
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we have transfected the cells with the Ϫ1099CAT reporter plasmid, a construct which contains the Ϫ1099/ϩ105 fragment of the human APP gene. As observed in the previous figures, the induction of APP by RA in SH-SY5Y cells requires at least 4 days, and this response appears to be very slow when compared with other responses induced by this ligand on these neuroblastoma cells. In agreement with those findings, Fig. 3 shows that in transient transfection assays, a 48 h incubation with RA strongly induces the activity of the RAR␤2 promoter, which contains a well- 63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100  101  102  103  104  105  106  107  108  109  110  111  112  113  114  115  116   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54 
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defined RARE (right panel), but is unable to induce APP promoter activity at that time period. The retinoid was able to induce APP promoter activity only after 4 -6 days of treatment (left panel). In addition, a computer-assisted study indicates that the APP gene promoter region, does not contain a consensus RARE, thus supporting an indirect mechanism, likely mediated by the previous induction of other protein/s, but not directly mediated by binding of RA receptors to a RARE in the APP gene promoter.
BDNF induces APP promoter activity in RA-pretreated cells
As we have previously described, BDNF stimulates the APP gene promoter in TrkB expressing SH-SY5Y cells, whereas it is unable to induce a response in control TrkBuntransfected cells (Ruiz-Leon and Pascual, 2001) . In addition, as has also been described, RA may regulate the expression of TrkB in neuroblastoma cell lines (Lucarelli et al., 1995) , which have become dependent on BDNF for survival (Feng et al., 2001 ). To test whether or not RA treatment could induce TrkB and confer BDNF responsiveness to the APP, we first determined the levels of TrkB in SH-SY5Y cells incubated for 4 days in the presence or in the absence of 1 M RA. As shown in panel A of Fig. 4 , RA induces the expression of the TrkB gene, increasing both the TrkB-mRNA (left) and TrkB protein (right) levels in SH-SY5Y cells after 4 days of treatment.
In addition, we have also analyzed the effects of BDNF on APP promoter activity in SH-SY5Y cells pretreated with RA. In order to analyze whether or not the RA-induced expression of TrkB is enough to confer BDNF responsiveness to the APP promoter, cells were incubated in the presence or in the absence of 1 M RA for 4 days, and then cotransfected with the 1099-CAT reporter plasmid (which contains the fragment Ϫ1099 to ϩ105 of the APP gene) and a TrkB-expressing vector, or the corresponding empty noncoding control vector. As shown at the left of panel B, treatment of RA-untreated cells with 10 ng/ml BDNF for 48 h leads to a significant increase of CAT activity in TrkB expressing transfected cells, but is unable 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52 53 54
to increase the basal activity in TrkB-untransfected cells, which express very low levels of TrkB. In contrast, as shown at the right side of the panel, CAT activity was significantly induced by BDNF in cells preincubated for 4 days in the presence of 1 M RA, even in the absence of transfected TrkB. Moreover, as illustrated in panel C of the figure, the levels of APP-mRNA induced by RA were markedly decreased in the presence of the trk inhibitor K-252a (0,2 M). Altogether, these results suggest that treatment of cells with RA which, as shown in panel A, is able to induce TrkB expression, is sufficient to confer BDNF responsiveness in APP promoter.
DISCUSSION
In the present work we have demonstrated that treatment with RA can induce TrkB expression in SH-SY5Y cells, and confer BDNF responsiveness to the APP gene promoter. The effects of RA are mediated by RAR, which belong to the subfamily of nonsteroid nuclear hormone receptors. SH-SY5Y cells, a neuroblastoma cell line of human origin, express RAR (Lovat et al., 1993) , and the expression of a number of genes has been described to be directly modulated by RA in these cells. Also in SH-SY5Y cells, 10 M RA has been reported to activate APP expression, specifically increasing the APP 695 -mRNA isoform, as proved by S1 nuclease protection assay (Konig et al., 1990) .
We have demonstrated that exposition to 1 M RA, a smaller and more physiological dose, is able to induce the expression of the APP gene increasing not only the total APP mRNA levels, but also the intracellular and extracellular content of APP. However, this response requires a relatively long exposition to RA (4 -6 days), and strongly suggests a non-direct mediated mechanism. Although with slight differences, these results are similar to those described by Beckman and Iverfeldt (1997) in the same cellular line. According to these authors, a higher dose of RA (10 M) induces an increase of the APP messenger levels, which appears to be significant only after 6 days of treatment.
The delayed response of the APP gene could be explained by the presence of low levels of RA receptor. Nevertheless, such a possibility appears to be diminished since as shown in Fig. 3 , the retinoid was unable to induce APP promoter activity in transient transfection assays at a time in which this compound is very effective in increasing the activity of the R-140-Luc construct (Vivanco-Ruiz et al., 1991) which contains the fragment Ϫ124 to ϩ14 of the human RAR␤2 promoter. In addition, a theoretical analysis of the APP gene, reveals that the APP promoter does not contains a consensus, or even an imperfect, RARE. These results strongly suggest that activation of APP by RA is not directly mediated by binding of RARs to sequences of the APP promoter, and may require the previous activation of other protein(s), which in turn could affect APP gene expression.
In this respect, it has been reported that RA effectively induces the expression of the BDNF receptor TrkB in neurons (Kaplan et al., 1993) . Both BDNF and TrkB, are highly expressed in the adult hippocampus, one of the most affected tissues in Alzheimer's disease, and we have previously described that BDNF induces APP expression in SH-SY5Y cells transiently expressing TrkB (Ruiz-Leon and Pascual, 2001 ). In addition, it has been suggested that RA may induce BDNF responsiveness of sympathetic neurons by alteration of Trk neurotrophin receptors expression (Kobayashi et al., 1994) . Therefore, the effects induced by RA on the APP expression in SH-SY5Y cells could be mediated by the previous increase of TrkB levels. Although SH-SY5Y cells express very low amounts of TrkB receptor, RA has been described to induce a sustained increase in TrkB-mRNA that is already detectable at the second day of treatment and leads to a significant elevation of TrkB levels (Kaplan et al., 1993) . In contrast, as has been also described, SH-SY5Y cells express TrkB, and RA specifically decreases TrkB-mRNA levels in the same cell line (Ehrhard et al., 1993) . Those discrepancies could be secondary to the experimental conditions maintained by both groups, or even due to specific cellular properties associated to the cellular clones of SH-SY5Y used. In order to validate our model we first analyzed the effects induced by RA on TrkB expression in our cells. Although with minor differences, our results are in agreement with those described by Kaplan et al. (1993) . We have found that 4 days of treatment with 1 M RA significantly increases the levels of both TrkB mRNA and protein, as determined by Northern and Western blot, respectively. Moreover, we have also found that RA induces BDNF responsiveness of the APP promoter, thus proving that RA-induced TrkB is functionally active. Without RA treatment, APP promoter activity was very low and was minimally induced by BDNF. In contrast, the neurotrophin led to a significant increase of APP promoter activity in cells exposed to RA for 4 days. As a control, in cells not exposed to RA, this response was only found after transfection of TrkB. Finally, the effects induced by RA on APP mRNA were substantially diminished in the presence of the Trk inhibitor K-252a, further confirming a TrkB-mediated mechanism.
BDNF, a member of the neurotrophin family, protects neurons against cellular insult (Cheng and Mattson, 1994) , and promotes survival in human neuroblastoma cells (Middlemas et al., 1999) . Furthermore, it has been suggested that neurodegeneration may be, at least in part, secondary to an alteration in BDNF and/or TrkB levels. In agreement with this hypothesis, the use of BDNF as a potential therapeutic agent in patients with Alzheimer's disease has been proposed (Ferrer et al., 1999; Mufson en al., 1999) . Our results suggest that RA may substantially intensify the effects of BDNF by increasing the expression of its receptor TrkB; this would open the possibility of using both agents, RA and BDNF in a coordinate way. Unfortunately, APP overexpression is also considered a risk factor for Alzheimer's disease. Therefore, both the beneficial effects induced by the neurotrophin on cellular survival, and the negative and toxic effects that accompany APP overexpression, should be considered. Moreover, although the molecular events that regulate the expression of TrkB and the effects induced by the BDNF/TrkB system in neurons Y. Ruiz-Leó n and A. Pascual / Neuroscience 000 (2003) 000 6 rich3/pn-nsc/pn-nsc/pn1603/pn6432d03a reedj Sϭ4 5/29/03 11:37 Art : Research paper 24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54 U N C O R R E C T E D P R O O F are poorly understood, it results plausible that BDNF-induced effects are controlled by RA, through a very sensitive and accurate mechanism which determines the levels of TrkB and hence the BDNF-induced effects. An exhaustive analysis of the mechanisms involved in the responses induced by RA on TrkB and APP would result of maximal interest for the development of therapeutic strategies.
Our results suggest that RA may substantially intensify the effects of BDNF by increasing the expression of its receptor TrkB, and it results plausible that BDNF-induced effects are controlled by RA, through a very sensitive and accurate mechanism which determines the levels of TrkB and hence the BDNF-induced effects. These results open the possibility of using both agents, RA and BDNF, coordinately, and this would be of maximal interest for the development of therapeutic strategies. However, it is evident that new experiments should be carried out to evaluate the physiological relevance of these findings. First, an important effort should be made to elucidate whether these mechanisms are also observed in vivo, and definitely prove that RA and BDNF functionally interact in neurons and intact tissues.
